Todos Medical Ltd. · OTC:TOMDF
Todos Medical — Investor Presentation (March 2018)
26 slides from Todos Medical's investor presentation, March 2018
Slide 1: Non Confidential Investor Presentation Q1/2018
Non Confidential Investor Presentation Q1/2018
Slide 2: Safe Harbor
Safe Harbor This presentation may contain forward-looking statements, including, without limitation, statements containing the words “believes”, “expects”, “plans”, ”estimates” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors w
Slide 3: TODOS Medical Company Vision
TODOS Medical Company Vision Creating a better and more affordable way of cancer screening to improve treatment and reduce mortality. 3
Slide 4: Company Mission
Company Mission • Blood test as first line method and standard of care for cancer screening. • Provide a simple and reliable cancer screening methods based on a blood sample. The Need The Vision There is currently no low cost and simple cancer Todos Medical aims to develop and bring to market detect
Slide 5: Executive Summary
Executive Summary TODOS Medical has developed a new cancer detection method that we believe will change the way cancers will be screened in the future. The method is low cost with high specificity and sensitivity. It is based on optical/biochemical inspection of blood components. Only 10cc of periph
Slide 6: Investment Highlights
Investment Highlights Innovation: Blood test based Platform: Strong IP on the total Scalable and Scalable Portfolio: biochemical easy to 3 patents infra-red analysis Platform implement for granted and of the immune new indications more pending system and plasma Global Presence: Scientific Singapore
Slide 7: Our Value Proposition
Our Value Proposition A robust cancer screening from a simple blood test that utilizes Total Biochemical Infrared Analysis (TBIA): in-vitro diagnostic method (IVD) based on spectral analysis of peripheral blood components – Quick – Simple (blood test) – Non invasive & radiation free – Automated resu
Slide 8: Company Products
Company Products Todos Breast Screens Todos Colon Screen TM-B1 & TM-B2 TM-C1 Our breast cancer blood Test is targeting a Colonoscopy is the current standard in large population of women that need to be Colorectal Cancer (CRC) testing. Our checked regularly for breast cancer, whether proprietary TM-C
Slide 9: Leadership
Leadership • Vice President of Medical Affairs and Clinical Development at Juniper Pharmaceuticals in Boston, MA since 2016. • Senior Director of Clinical Development for Women's Health and Global Head of Women's Health Medical Affairs at Teva Pharmaceuticals. Dr. Herman Weiss • Chief Medical Office
Slide 10: Global Cancer Diagnostics Market Overview
Global Cancer Diagnostics Market Overview 2015 Market Snapshot (USD Billions) • The global cancer diagnostics market was valued at $114.5 billion USD in 2015. • By Screening Types: Imaging ($28.3B), Genetic Tests ($25.8B), and Laboratory Tests ($25.7B) each account for about a fourth of the market.
Slide 11: Market Driver Analysis (1 of 4)
Rising Incidence Market Driver Analysis (1 of 4) of Cancer • Cancer is a leading cause of death worldwide. According to the National Cancer Institute at the National Institutes of Health, around 8.2 million cancer deaths and 14 million new cases were registered in 2012. • The following chart depicts
Slide 12: Application Movement Analysis: Breast Cancer
Application Movement Analysis: Breast Cancer • Breast cancer has the largest prevalence rate. About 1 in 8 U.S. women develop invasive breast cancer as per the U.S. breast cancer statistics. It also reports that 246,660 new cases of invasive breast cancer are expected to occur in 2016. • Most of the
Slide 13: Application Movement Analysis: Colorectal Cancer
Application Movement Analysis: Colorectal Cancer • Colorectal cancer is a malignant type of cancer arising from the inner wall of large intestine. • According to National Cancer Institute, it is third most common type of cancer in men and women in the U.S. • Colorectal cancer can be hereditary in a
Slide 14: Large & Growing Addressable Market
Large & Growing Addressable Market • In women, breast cancer has the highest incidence rate • In women and men, colorectal cancer has the 3rd highest incidence rate Breast Cancer Screening Colorectal Cancer Screening Eligible Candidates Market Eligible Candidates Market In the EU, In the U.S., 64 M
Slide 15: Todos Medical Solution
Todos Medical Solution • No change to the standard practices for blood tests • Proprietary technology to analyze blood and detect the presence of various cancers • Todos Kit – specially prepared kit, including special glass slide and salt solution needed for the blood separation process, to ensure a
Slide 16: Cloud Based Solution
Cloud Based Solution Todos Medical Data Warehouse Todos Sell a Kit to the lab or clinic Patient Data from lab + Results FTIR Spectrum File Hematologic Lab 16
Slide 17: Innovative Technology (Immune respond and FTIR)
Innovative Technology (Immune respond and FTIR) • Total Biochemical Infrared Analysis (TBIA) – FTIR spectroscopic analysis of cancers’ impact on the immune system – Most biomarkers’ assays depend upon a single or several markers which are directly related to the tumor – TBIA observes the biochemical
Slide 18: Combined FTIR Analysis of PBMC and Plasma
The Technology Combined FTIR Analysis of PBMC and Plasma Combined Plasma and PBMCs analysis results in high sensitivity & specificity test 18
Slide 19: Challenges With Current Detection Methods
Challenges With Current Detection Methods Breast Cancer – • Mammography Low – Cost: approx. $200 Sensitivity – Approx. 50% of women are poorly diagnosed and – Indeterminate mammograms require follow-up Specificity with MRI, 3D mammography and biopsies – High false positive cancer diagnosis rate (cas
Slide 20: Challenges with Detection Methods (Cont.)
Challenges with Detection Methods (Cont.) Colorectal Cancer – • Colonoscopy – Cost: ~$1,000 – Difficult preparation process; fasting and invasive procedure – Approx. 60% of patients refuse to undergo a Poor Early colonoscopy; and about 80% adhere to blood Detection test – Low patience compliance con
Slide 21: The Solution Trifecta
The Solution Trifecta • Todos’ solution is a triple win appealing to all three participants Patient - Simple blood test - Early cancer detection Payer Physician - Low cost test - Patient compliance - Saving on expensive treatment - Fast detection for early stages 21 1) Based on latest clinical trial
Slide 22: Comparable Companies
Comparable Companies Todos Medical Exact Science Volition RX Epigenomics Provista TOMDF EXAS VNRX EPGNF Diagnostics IVD / CRC+ Breast Stool / CRC IVD CRC IVD CRC IVD Breast Early Stage Detection PPP P PP P NA Sensitivity & Specificity in PPP PPP PP PP PPP advanced cancer Target Population PPP P NA P
Slide 23: A Superior Solution
A Superior Solution Competing Tests • Immune system indication – The only test that looks at the immune system to identify the presence of cancer • Results – Early stage cancer detection – Sensitivity and specificity in advanced cancer – Increased compliance and prevention • Simple Process – Simple
Slide 24: Clinical Support for Feasibility in Breast and Colorectal Cancer Screening
Publications on Clinical Results Clinical Support for Feasibility in Breast and Colorectal Cancer Screening Four Peer Reviewed Publications Over 80% sensitivity and over 80% specificity achieved in most recent studies • June 2015, Colorectal Cancer Screening: Barlev et al. Journal of Gastroenterolog
Slide 25: Intellectual Property (IP) Portfolio
Intellectual Property (IP) Portfolio • TODOS Medical has the exclusive worldwide rights to use the IP for commercial and R&D purposes. Three patents are currently granted: Patent Number Description Issue Date Exp. Date Category I: These applications relate to analysis of an IR spectrum of a PBMC sam
Slide 26: Thank You! For Additional Information
Thank You! For Additional Information: Rami Zigdon CEO Telephone: +972-54-638-0666 | Main Office: +972-8-633-3964 [email protected]